Genmab - ADR
GMAB
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.19B
Close$
$6.26
80% downside
Current Fair Value
80% downsideOvervalued by 80% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.19 Billion |
|---|---|
| Enterprise Value | $23.04 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.55 |
| Beta | 0.69 |
| Outstanding Shares | 613,836,700 |
Return
| Return on Equity | 17.37% |
|---|---|
| Return on Assets | 7.98% |
| Return on Invested Capital | 24.00% |
Valuation & Multiples
| P/E Ratio | 23.24 |
|---|---|
| PEG | -31.96 |
| Price to Sales | 2.09 |
| Price to Book Ratio | 3.48 |
| Enterprise Value to Revenue | 2.41 |
| Enterprise Value to EBIT | 8.57 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | 0.95 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.37
Average shareholder expectationRevenue Estimate
$1.12 B
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.36
Average shareholder expectationRevenue Estimate
$1.21 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0700▲ 4.39% |
|---|---|
| Total Calls | 44,300▼ 89.28% |
| Total Puts | 3,100▼ 71.30% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.75%▼ 11.53% |
|---|---|
| Total Invested | $294.53M▼ 86.81% |
| Investors Holding | 124▼ 155.00% |
ESG Score
No data
About Genmab
CEO: Jan van de Winkel